Coronary atherosclerosis can regress with very intensive statin therapy

Ilke Sipahi, Stephen J. Nicholls, E. Murat Tuzcu, Steven E. Nissen

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.

LanguageEnglish
Pages937-944
Number of pages8
JournalCleveland Clinic journal of medicine
Volume73
Issue number10
Publication statusPublished - Oct 2006
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Sipahi, I., Nicholls, S. J., Tuzcu, E. M., & Nissen, S. E. (2006). Coronary atherosclerosis can regress with very intensive statin therapy. Cleveland Clinic journal of medicine, 73(10), 937-944.
Sipahi, Ilke ; Nicholls, Stephen J. ; Tuzcu, E. Murat ; Nissen, Steven E. / Coronary atherosclerosis can regress with very intensive statin therapy. In: Cleveland Clinic journal of medicine. 2006 ; Vol. 73, No. 10. pp. 937-944.
@article{c072f141bc7a46498177ebe6925d86df,
title = "Coronary atherosclerosis can regress with very intensive statin therapy",
abstract = "The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15{\%}. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.",
author = "Ilke Sipahi and Nicholls, {Stephen J.} and Tuzcu, {E. Murat} and Nissen, {Steven E.}",
year = "2006",
month = "10",
language = "English",
volume = "73",
pages = "937--944",
journal = "Cleveland Clinic journal of medicine",
issn = "0891-1150",
publisher = "Cleveland Clinic Educational Foundation",
number = "10",

}

Sipahi, I, Nicholls, SJ, Tuzcu, EM & Nissen, SE 2006, 'Coronary atherosclerosis can regress with very intensive statin therapy', Cleveland Clinic journal of medicine, vol. 73, no. 10, pp. 937-944.

Coronary atherosclerosis can regress with very intensive statin therapy. / Sipahi, Ilke; Nicholls, Stephen J.; Tuzcu, E. Murat; Nissen, Steven E.

In: Cleveland Clinic journal of medicine, Vol. 73, No. 10, 10.2006, p. 937-944.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Coronary atherosclerosis can regress with very intensive statin therapy

AU - Sipahi, Ilke

AU - Nicholls, Stephen J.

AU - Tuzcu, E. Murat

AU - Nissen, Steven E.

PY - 2006/10

Y1 - 2006/10

N2 - The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.

AB - The ASTEROID trial (JAMA 2006; 295:1556-1565) showed that very intensive statin therapy with rosuvastatin 40 mg once daily results in highly significant regression of coronary atherosclerosis as assessed by serial intravascular ultrasonography (IVUS). The mean low-density lipoprotein cholesterol (LDL-C) level achieved with this regimen was 61 mg/dL, and the mean high-density lipoprotein cholesterol (HDL-C) level increased by 15%. While the merits of concomitant LDL-C-lowering and HDL-C-raising therapies remain to be determined, the results of the ASTEROID and other recent trials suggest that the optimal strategy for lipid-lowering in patients with coronary artery disease is to try for the lowest LDL-C level that can be attained without adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=33750052563&partnerID=8YFLogxK

M3 - Article

VL - 73

SP - 937

EP - 944

JO - Cleveland Clinic journal of medicine

T2 - Cleveland Clinic journal of medicine

JF - Cleveland Clinic journal of medicine

SN - 0891-1150

IS - 10

ER -

Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE. Coronary atherosclerosis can regress with very intensive statin therapy. Cleveland Clinic journal of medicine. 2006 Oct;73(10):937-944.